Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

Abstract

Febrile neutropenia remains a common occurrence among patients receiving myelosuppressive chemotherapy and typically results in extended hospitalization and, for many patients, death. A minority of patients are, however, treated exclusively on an outpatient basis.